Business Description
Accustem Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US00444A1016
Description
Accustem Sciences Inc is a life sciences company that focuses on enhancing cancer patient outcomes through diagnostic, pharmaceutical, and medical device products. Their flagship product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services. Operations span New York, NY, and London, UK.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.38 | |||||
| Equity-to-Asset | -15.76 | |||||
| Debt-to-Equity | -0.03 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.28 | |||||
| 9-Day RSI | 36.83 | |||||
| 14-Day RSI | 37.81 | |||||
| 6-1 Month Momentum % | -46.74 | |||||
| 12-1 Month Momentum % | -75.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.06 | |||||
| Quick Ratio | 0.06 | |||||
| Cash Ratio | 0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -1.45 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -502.94 | |||||
| ROIC % | -1703.49 | |||||
| ROC (Joel Greenblatt) % | -34183.33 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -1.54 | |||||
| EV-to-EBITDA | -1.55 | |||||
| EV-to-FCF | -2.09 | |||||
| Earnings Yield (Greenblatt) % | -64.94 | |||||
| FCF Yield % | -51.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ACUT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Accustem Sciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.17 | ||
| Beta | 0 | ||
| Volatility % | 107.63 | ||
| 14-Day RSI | 37.81 | ||
| 14-Day ATR ($) | 0.019292 | ||
| 20-Day SMA ($) | 0.291568 | ||
| 12-1 Month Momentum % | -75.33 | ||
| 52-Week Range ($) | 0.2707 - 1.95 | ||
| Shares Outstanding (Mil) | 11.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Accustem Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Accustem Sciences Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Accustem Sciences Inc Frequently Asked Questions
What is Accustem Sciences Inc(ACUT)'s stock price today?
The current price of ACUT is $0.28. The 52 week high of ACUT is $1.95 and 52 week low is $0.27.
When is next earnings date of Accustem Sciences Inc(ACUT)?
The next earnings date of Accustem Sciences Inc(ACUT) is .
Does Accustem Sciences Inc(ACUT) pay dividends? If so, how much?
Accustem Sciences Inc(ACUT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers